
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dexmethylphenidate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Cingulate Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences
Details : The agreement aims for the manufacturing of CTx-1301(dexmethylphenidate HCl), the company’s lead asset for the treatment of attention deficit/hyperactivity disorder (ADHD).
Product Name : CTx-1301
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 17, 2025
Lead Product(s) : Dexmethylphenidate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Cingulate Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
